LDHAL6B

Across TCGA pan-cancer cohorts, LDHAL6B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated LDHAL6B data layer compared with 27 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher LDHAL6B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated LDHAL6B expression acts as an unfavorable survival marker.

LUSC, KIRC, and UCEC are the cancer types where LDHAL6B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	III,IV	0.112	0.664	.003	12	view →
KIRC	OS	Median	All	0.181	0.655	.046	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	III,IV	0.233	0.705	.034	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

LDHAL6B–LUSC (OS)

Open the LUSC breakdown →